Is the price fair?
What LIVN's price assumes
LivaNova PLC trades at 41.0× earnings against 33.4× for the median Medical Devices name, more expensive than its own group.
41.0
Trailing P/E · Medical Devices median 33.4 · 1.23× the median: the market pays up for this one
- Price / sales
- 2.48
Price / sales · as of 2026-Q1
- Free cash flow yield
- 3.7%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +9.5%
Growth the price implies · The price pays for +9.5% free cash flow growth a year for a decade; the business has delivered +65% a year over the last three.
Details›
- Price / book2026-Q1
- 2.94
- EV / EBIT2026-Q1
- 17.2
- EV / sales2026-Q1
- 2.30
- Healthcare median P/E362 names
- 31.5
- Medical Devices median P/E39 names
- 33.4
- Free cash flow, trailing twelve months
- $161M
- Market capitalisation
- $4.31B
- 3-year revenue growth
- +11%
- 3-year free cash flow growth
- +65%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.